Home Infusion for Multiple Sclerosis: Ocrevus, Tysabri, and What Patients Should Know
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system in which the immune system attacks the myelin sheath surrounding nerve fibers, disrupting signal transmission and causing progressive neurological symptoms. For patients with relapsing MS and certain forms of progressive MS, high-efficacy IV biologic therapies have become a cornerstone of disease management.
Receiving these infusions through home infusion therapy is an established option for appropriate patients, eliminating the need for repeated infusion center visits every six months or four weeks. Pharmko supports MS patients and their neurologists across 22+ states with full clinical coordination and nursing support.
IV Biologic Therapies Used in Multiple Sclerosis
Ocrevus (ocrelizumab)
Ocrevus is an anti-CD20 monoclonal antibody that depletes B cells, a key driver of MS inflammation and neurodegeneration. It is FDA-approved for both relapsing MS and primary progressive MS (PPMS), making it the first therapy approved for PPMS. Ocrevus is administered twice yearly by IV infusion, with the first dose split into two infusions two weeks apart.
Each infusion takes approximately 3.5 hours for subsequent doses (the initial doses take up to 5 hours due to slower administration rates). Vital sign monitoring is required throughout. Pre-medications, methylprednisolone, an antihistamine, and acetaminophen, are given before each infusion to reduce the risk of infusion-related reactions.
Tysabri (natalizumab)
Tysabri is an alpha-4 integrin inhibitor that prevents immune cells from crossing into the central nervous system. It is administered monthly by IV infusion over approximately one hour. Tysabri is highly effective for relapsing MS but carries a risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection caused by the JC virus, that requires regular monitoring and patient stratification.
Patients on Tysabri are tested for JC virus antibodies periodically, and their neurologist determines whether the benefit-risk profile supports continued therapy. This monitoring context is an important part of home infusion coordination.
Lemtrada (alemtuzumab)
Lemtrada is administered in two treatment courses, a 5-day course in year one and a 3-day course in year two, typically in a supervised clinical setting due to its intensive monitoring requirements. It is not commonly administered at home, but post-treatment monitoring visits can be coordinated through Pharmko when clinically appropriate.
Who Qualifies for Home Infusion of MS Biologics?
Home infusion for MS therapies is appropriate for patients who have:
- Completed their initial infusion doses in a supervised clinical or infusion center setting without significant reactions
- Received pre-infusion medications per protocol and tolerated them without complications
- Been assessed by their neurologist as stable and suitable for home-based administration
- A home environment that supports safe IV infusion with nursing oversight
The decision is made in collaboration between the patient and neurologist. Pharmko works directly with neurology practices to manage the clinical handoff from infusion center to home.
What to Expect During a Home MS Infusion
Before the infusion
A Pharmko nurse reviews your current medications, confirms you have no active infections, and administers pre-medications as ordered. Baseline vital signs are taken and documented.
During the infusion
Your nurse remains present for the full infusion, monitors vital signs at scheduled intervals, and responds immediately to any infusion-related reaction. The rate is slowed or the infusion paused if you experience flushing, chest tightness, or other symptoms.
After the infusion
Vital signs are checked before the nurse departs. Your neurologist's office receives a clinical summary. Know which symptoms require an immediate call after an Ocrevus or Tysabri infusion, delayed reactions can occur in the 24 hours following treatment.
Insurance Coverage for MS Infusion Therapy
Ocrevus and Tysabri are covered under the medical benefit by Medicare Part B and most commercial insurance plans. Prior authorization is required and must include documentation of MS diagnosis, relapse history, and prior treatment history. Pharmko manages the authorization process and coordinates with your neurologist's office to compile the necessary clinical documentation.
For patients interested in a broader overview of biologic therapies for autoimmune conditions, our guide on home infusion for autoimmune diseases provides useful context across conditions.
→ Contact Pharmko to start a referral: 1-877-540-2003













